Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSFL-NK13
- Development stage
- Preclinical
- Modality
- Peptides
01
Overview
PSFL-NK13 is an engineered peptide designed for cancer immunotherapy that selectively disrupts the costabilization of CD47 and integrin αvβ3 on the surface of cancer cells. This costabilization facilitates immune evasion by strengthening the CD47-SIRPα "don't eat me" signal, which inhibits macrophage-mediated phagocytosis. Because this specific interaction is absent on erythrocytes, PSFL-NK13 avoids the treatment-limiting anemia often associated with broad CD47 inhibitors. Preclinical studies indicate that PSFL-NK13 enhances macrophage phagocytosis, delays tumor growth, and inhibits angiogenesis without significant hematologic toxicity.
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on PSFL-NK13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSFL-NK13.